A spirin has emerged as a remarkably safe, inexpensive, and effective drug for the secondary prevention of the complications of atherosclerotic disease. It acts by inhibiting the enzyme prostaglandin (PG) G/H synthase, actually a bifunctional protein that sequentially catalyzes the conversion of arachidonic acid to the highly reactive endoperoxide intermediates PGG 2 and PGH 2 via its cyclooxygenase (COX) and peroxidase functions. This enzyme, colloquially termed COX, has been crystallized 1 and the mechanism of action of aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) elucidated. [2] [3] [4] The catalytic site is buried deep within the core of the enzyme and is accessed by the substrate via a hydrophobic tunnel. Aspirin irreversibly acetylates a serine residue at position 529 in the human enzyme, 5 close to but not at the catalytic site, though still blocking access to it by the arachidonic acid substrate. NSAIDs, by contrast, act reversibly as competitive inhibitors at the catalytic site. Indeed, transient occupancy of that site after dosing with an NSAID may mask the serine from the effects of a subsequent dose of aspirin. 6 
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The beneficial effects of aspirin in cardiovascular disease have been attributed to its inhibitory effects on COX in platelets. In these cells, thromboxane (Tx) synthase further catalyzes the conversion of PGH 2 to TxA 2 , 7 which exerts proaggregatory, vasoconstrictor, and proliferative effects via a membrane-bound, G protein-coupled receptor, the TP. 8 Two isoforms (␣ and ␤) of the TP have been cloned, 8, 9 both of which are transcribed in human platelets, although only TP␣ appears to be translated. 10 Transcripts of both isoforms are present in vascular cells. 11 Although the isoforms differ in their rates of agonist-induced desensitization 12 and propensity to couple with G proteins, 13 little is known of their disparate roles in vivo. The importance of TxA 2 in platelet activation is thought to derive principally from its role as an amplifying signal for other stronger, primary agonists, such as thrombin and ADP. 14 However, the clinical efficacy of aspirin complements that of ticlopidine, 15 a drug that selectively inhibits platelet aggregation induced by ADP but not TP agonists ex vivo. Clopidogrel, a close relative of ticlopidine, appears to act by a similar mechanism. 15 In a large-scale clinical trial, clopidogrel emerged as slightly more efficacious than aspirin in the secondary prevention of myocardial infarction and stroke. 16 The irreversible acetylation of Ser529 by aspirin in the COX of anucleate platelets explains the cumulative inhibition of the capacity of platelets to generate TxA 2 , commonly measured as serum concentrations of its hydrolysis product TxB 2 . Thus, daily administration of 75 mg of aspirin takes 3 to 4 days to inhibit completely serum TxB 2 ex vivo. 17 Interestingly, like low-dose aspirin, 75 mg of clopidogrel also takes several days to inhibit platelet function ex vivo, perhaps owing to the gradual accumulation of a metabolite that binds to a subclass of purinergic receptors, although this has yet to be established in vivo. As in the case of aspirin, loading doses of clopidogrel have been investigated and are likely to be employed in acute settings of vascular occlusion. Studies designed to assess the potentially additive effects of aspirin with clopidogrel have been initiated. Finally, dipyridamole has been reformulated to correct prior problems with variable and transient bioavailability. This new preparation has been shown to be as effective as low-dose aspirin in the secondary prevention of stroke, and the benefit from a combination of the 2 is roughly additive. 18 This has led to the US Federal Drug Administration approval of an aspirin-dipyridamole combination for this indication. Although oral inhibitors of the platelet glycoprotein ␣IIb/␤III have been disappointing, 3 antiplatelet drugs-low-dose aspirin, clopidogrel, and dipyridamole-have been proven effective in the secondary prevention of cerebrovascular and/or cardiovascular disease. Their mechanisms of action suggest that their benefits might be additive, although this remains to be established in a clinical trial. This has "raised the bar" for the development of potentially novel therapies in this arena.
The advent of pharmacological inhibitors of the TP 19 -21 inauspiciously coincided with the initial trials establishing the efficacy of aspirin in cardiovascular disease. [22] [23] [24] This confounded their development in 2 ways. First, as the effects of aspirin were attributed to inhibition of TxA 2 , TP antagonists had little additional benefit to offer. Perhaps preservation of the ability of the vasculature to generate other PGs such as prostacyclin (PGI 2 ) was a plus, but this was a strictly theoretical concept. Against that, it was difficult for TP antagonists to compete against aspirin at 20 cents a tablet. Two clinical trials of TP antagonists were performed, both addressing the possibility that they might modify restenosis after angioplasty.
In the CARPORT (Coronary Artery Restenosis Prevention on Repeated Thromboxane A 2 antagonism) study, the antagonist GR32191, given before percutaneous transluminal coronary angioplasty (PTCA) and for 6 months thereafter, did not differ significantly from the effects of intravenous aspirin given immediately before PTCA on luminal diameter as assessed by angiography performed 6 months after the intervention. 25 However, the limitations of this uncontrolled experience and of relying on an angiographic end point at a single time were highlighted by the M-HEART (MultiHospital Eastern Atlantic Restenosis Trial) II study. 26 In that study, all patients received aspirin before PTCA due to its role, by then established, in the prevention of periprocedural myocardial infarction 27 but were randomized to continuing treatment with the TP antagonist sulotroban, aspirin, or placebo. In this case, the angiographic estimate of vascular occlusion at 6 months was a secondary end point and did not differ between the groups. By contrast, continued treatment with either aspirin or sulotroban significantly reduced the later myocardial infarction rate in the 6 months after PTCA when compared with the placebo group. These observations left many unanswered questions. First, aside from there being no measure of the degree of synthesis inhibition achieved by aspirin or of TP blockade by either antagonist, the divergence of the time-integrated clinical and "snapshot" angiographic end points in the M-HEART II study illustrated the limited information available from CARPORT. Second, the hypothesis that TP blockade might be superior to aspirin was configured on the preservation of PGI 2 formation during TP blockade. PGI 2 has significant antiproliferative effects. Both virally delivered PGI synthase and a PGI 2 analogue, beraprost, have been shown to reduce significantly the proliferative response to experimental angioplasty. 28, 29 However, the procedure-related increase in PGI 2 biosynthesis, like that in TxA 2 , is short-lived and suppressed by aspirin in patients undergoing PTCA, 30, 31 and the patients assigned to sulotroban were receiving aspirin at that time.
Cayette and colleagues 32 now report observations that suggest that reconsideration of the role of TP antagonism is timely. Using a newly synthesized TP antagonist, S18886, which is devoid of partial agonist activity, they report that atherogenesis can be retarded in the apoE-knockout (KO) mouse. Oddly, aspirin has no effect. One possibility is that inhibition of other COX products by aspirin, such as PGI 2 , might have obscured a benefit from inhibiting TxA 2 . We now know that deletion of the PGI 2 receptor-the IP-results in an increased response to thrombotic stimuli in vivo, 8 but the role of this mediator in atherogenesis is unknown. We also now know that there are 2 forms of COX. 4 The second isoform is a distinct gene product and is readily regulated in its expression by growth factors, tumor promoters, and cytokines. The tertiary structures of the 2 enzymes are remarkably similar 4 ; however, the hydrophobic channel of COX-2 is more accommodating. Both COX isozymes form small amounts of 11(S)-and 15(S)-hydroxyeicosatetraenoic acids (HETEs). It is unknown whether they contribute to COX actions in vivo, although some HETEs have been shown to be weak TP agonists in vitro. 15(S)-HETE can also be formed as a primary product by the 15-lipoxygenase enzyme. Deletion of this enzyme reverses atherogenesis in the apoE-KO mouse. 33 Interestingly, unlike the case with COX-1, inhibition of COX-2-dependent PG synthesis by aspirin, but not by NSAIDs, ex vivo or in vitro is accompanied by increased generation of both 11-and 15-HETEs, but now in the R stereoconfiguration. The acetyl residue is thought to force realignment of the end of the arachidonic acid carbon chain, which is usually oriented in an L-shaped configuration in the hydrophobic channel. 34 Mutation to their COX-1 equivalents of 3 residues predicted to be critical to the spatial and flexibility differences in the COX-2 channel abolishes this feature in the mouse enzyme. 35 Both COX isoforms are present, with remarkably similar distributions, in human atherosclerotic plaque. 36 Although this may also be true in the atherosclerotic mouse, it is unknown whether 15(R)-HETE has any biological effects in aspirin-treated animals. Thus for now, the role of TP activation by HETEs in explaining the discrepancy between the effects of aspirin and the TP antagonist in the study of Cayette and colleagues 32 remains quite speculative. Perhaps the explanation is more mundane. The relationship between inhibition of the capacity of platelets to generate TxA 2 -estimated by serum TxB 2 -and inhibition of Tx-dependent platelet activation is remarkably nonlinear. Just 5% residual capacity is sufficient fully to sustain function. 37 In the present study, the aspirin regimen suppressed serum TxB 2 by only 70% to 75%, and TPdependent platelet activation is likely to have been unimpaired. Clearly, platelets may be a source of growth factors relevant to atherogenesis, but activation of TPs in other cells may also be relevant. In tissues other than the platelet, we have no information as to the relationship between biosynthetic capacity and function.
Cayette and colleagues 32 raise the possibility that the discrepant results between aspirin and S 18886 might also be explained if isoprostanes (iPs), free radical-catalyzed products of arachidonic acid, played an important role in TP activation. Indeed, at least 2 iPs-iPF 2␣ -III (also known as 8-iso-PGF 2␣ 38 ) and iPE 2 -III-exert potent effects on platelet function and vascular tone, and these actions are prevented by TP antagonists and absent in TP-deficient mice. 39 Generation of iPs is increased in both humans with atherosclerosis 40 and in apoE-KO mice, and iP suppression with vitamin E retards atherogenesis in this model. 41 Perhaps the use of TP antagonists should be reconsidered in other syndromes in which oxidant stress and COX activation coincide, such as occlusion/reperfusion and inflammation. We are at a very early stage in elucidating the biological actions of iPs and related compounds, some of which may act as incidental ligands at other PG receptors. 42 Where do the observations of Cayette and colleagues 32 lead us? It would certainly be interesting to confirm the effects of the compound in murine models more reminiscent of the human disease. 43 It would also be reassuring to confirm that similar effects are observed with structurally distinct antagonists and TP deletion. It remains a formal possibility that the observed effects relate to properties of S 18886 that are unrelated to TP antagonism. Such studies will also increase our sense of the magnitude of the effect we might anticipate with TP antagonism. This seems consistent, but somewhat modest, in the apoE-KO mouse. Should such studies reinforce our confidence, modern imaging modalities such as electron beam CT of the coronary 44 or ultrasonography of the carotid arteries 45 afford noninvasive approaches to assess the impact of TP antagonism on plaque progression in humans. Reagents are now available for the study of TP expression in human disease, 46 and model systems have implicated TP activation in settings previously not considered when these drugs were under development. 47 Finally, TP antagonists may even be worth considering as alternative platelet inhibitors to aspirin in certain circumstances. For example, because platelets express COX-1 only, selective inhibitors of COX-2 do not afford cardioprotection. However, in the absence of any actual clinical data, the empiric combination of these drugs with low-dose aspirin has some theoretical limitations. Even low-dose aspirin causes gastrointestinal side effects, 48 which may erode the postulated benefit of selective COX-2 inhibition on the gastrointestinal tract. By contrast, TP antagonism has been shown to protect against NSAID-induced enteropathy in the rat. 49 Similarly, selective COX-2 inhibitors, NSAIDs, and even low doses of conventionally formulated aspirin depress PGI 2 biosynthesis in healthy individuals. 50, 51 Combination of TP antagonists with COX-2 inhibitors would afford at least similar cardioprotection to that of aspirin 25 while sparing PGI 2 formation from further suppression.
In summary, the provocative studies of Cayette et al 32 draw attention to a class of compounds that were previously abandoned for reasons that were rational at the time. Now that we know more about the breadth of potential TP ligands and are increasingly informed of the biology of PGs as a result of the availability of receptor-deficient mice, it would seem worthwhile to reconsider the contemporary utility of this interesting class of compounds.
